Producer of Advamed 2012, Ray Briscuso Leads One of The Largest MedTech Conferences in a New Direction
AdvaMed 2012, the big medtech conference for industry executives, has launched its website and is calling for proposals for program panels.
Blog
This Week In Diagnostics
Peter Winter, consultant to the biotechnology industry brings us financings and business developments in the global diagnostics business in his column “This Week In Diagnostics“. Peter has over 30 years experience as a scientist, science journalist, and publisher.
“Inside the FDA” session at BIO CEO Addressed PDUFA and TREAT Acts
This is one of the largest sources of frustration currently among health care companies and investors.
This Week in Diagnostics
Peter Winter, consultant to the biotechnology industry brings us financings and business developments in the global diagnostics business in his column “This Week In Diagnostics“. Peter has over 30 years experience as a scientist, science journalist, and publisher.
BIO CEO & Investor Conference Has Grown in Size and Offered Insight on Industry Mood
According to BIO’s statistics, “a majority of investors (56%) still think now is a good time to invest.
Intellect Neurosciences Files New Patent Applications for Immunotherapy Methods in Treatment of Alzheimer’s Disease
Over the next 40 years, caring for individuals with Alzheimer’s will cost American society $20 trillion –including $15 trillion to Medicare and Medicaid.
Spherix Closes Registered Direct Offering Of $1.15 Million In Common Stock And Warrants
Spherix has entered into definitive agreements to sell $1.15 million of shares of its common stock and warrants.
Will Contrast-Induced Nephropathy Kill You?
Contrast-induced nephropathy (CIN) is a form of acute renal failure precipitated by exposure to these radiocontrast agents. In other words, it is hospital-acquired. The question is: will it kill you?
Wound Management Sells Non-Core Subsidiary; Intends to Focus on CellerateRX and Medical Device Business
In total, over $500,000 in debt was removed from the balance sheet of Wound Management.
TONIX Pharmaceuticals Completes $4.3 Million Private Placement Funding
The company received net proceeds of approximately $1.9 million in the offering and converted an additional $1.9 million in previously convertible debentures as part of the offering.